Mustang Bio (MBIO) surged higher the prior week, after it highlighted substantially positive data in a phase 1/2 study using its gene therapy to treat patients with X-linked severe combined immunodeficiency ((XSCID)). It was shown that treatment with MB-107 was able to restore the immune system for these patients with the disease. This bodes well for the biotech's gene therapy program, as long as data can continue to be reproduced in a larger group of patients. Mustang Bio's gene therapy program is only a small part of its pipeline, because the other larger